Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.

Abstract

OBJECTIVES:

Long-term safety and efficacy of adalimumab among patients with juvenile idiopathic arthritis (JIA) was evaluated through 6 years of treatment.

METHODS:

Children aged 4-17 years with polyarticular JIA were enrolled in a phase III, randomised-withdrawal, double-blind, placebo-controlled trial consisting of a 16-week open-label lead-in period, 32-week randomised double-blind period and 360-week long-term extension. Patients were stratified by baseline methotrexate use. Adverse events (AEs) were monitored, and efficacy assessments included JIA American College of Rheumatology (JIA ACR) 30%, 50%, 70% or 90% responses and the proportions of patients achieving 27-joint Juvenile Arthritis Disease Activity Score (JADAS27) low disease activity (LDA, ≤3.8) and inactive disease (ID, ≤1).

RESULTS:

Of 171 patients enrolled, 62 (36%) completed the long-term extension. Twelve serious infections in 11 patients were reported through 592.8 patient-years of exposure. No cases of congestive heart failure-related AEs, demyelinating disease, lupus-like syndrome, malignancies, tuberculosis or deaths were reported. JIA ACR 30/50/70/90 responses and JADAS27 LDA were achieved in 66% to 96% of patients at week 104, and 63 (37%) patients achieved clinical remission (JADAS27 ID sustained for ≥6 continuous months) during the study. Attainment of JIA ACR 50 or higher and JADAS27 LDA or ID in the initial weeks were the best predictors of clinical remission. Mean JADAS27 decreased from baseline, 22.5 (n=170), to 2.5 (n=30) at week 312 (observed analysis).

CONCLUSIONS:

Through 6 years of exposure, adalimumab was well tolerated with significant clinical response (up to clinical remission) and a relatively low retention rate.

• Authors: Daniel J Lovell, Hermine I Brunner, Andreas O Reiff, Lawrence Jung, Katerina Jarosova, Dana Němcová, Richard Mouy, Christy Sandborg, John F Bohnsack, Dirk Elewaut, Christos Gabriel, Gloria Higgins, Isabelle Kone-Paut, Olcay Y Jones, Veronika Vargová, Elizabeth Chalom, Carine Wouters, Ivan Lagunes, Yanna Song, Alberto Martini, Nicolino Ruperto
• Journal: RMD open (RMD Open) Vol. 6 Issue 2 (07 2020) ISSN: 2056-5933 [Electronic] England
• PMID: 32665432 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

Chemical References

• Antirheumatic Agents
• Adalimumab
• Methotrexate

Topics

• Adalimumab (administration & dosage, therapeutic use)
• Adolescent
• Antirheumatic Agents (administration & dosage, therapeutic use)
• Arthritis, Juvenile (drug therapy, etiology, pathology)
• Child
• Child, Preschool
• Clinical Trials, Phase III as Topic
• Drug Therapy, Combination
• Duration of Therapy
• Female
• Humans
• Male
• Methotrexate (administration & dosage, therapeutic use)
• Prognosis
• Proportional Hazards Models
• Treatment Outcome